Synthetic Biologics Inc (NYSEMKT:SYN) was downgraded by equities researchers at Laurentian from a “buy” rating to a “speculative buy” rating in a research report issued to clients and investors on Friday.
Several other research analysts also recently commented on SYN. Zacks Investment Research upgraded Synthetic Biologics from a “hold” rating to a “buy” rating and set a $2.00 price objective on the stock in a report on Tuesday, August 9th. FBR & Co restated a “buy” rating on shares of Synthetic Biologics in a report on Friday, August 5th. BTIG Research initiated coverage on Synthetic Biologics in a report on Thursday, August 25th. They set a “buy” rating and a $5.00 price objective on the stock. Griffin Securities set a $5.80 price objective on Synthetic Biologics and gave the stock a “buy” rating in a report on Wednesday, August 31st. Finally, Laurentian Bank of Canada downgraded Synthetic Biologics from a “buy” rating to a “speculative buy” rating in a report on Friday. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $5.41.
Shares of Synthetic Biologics (NYSEMKT:SYN) opened at 0.8504 on Friday. The firm has a 50-day moving average price of $1.33 and a 200 day moving average price of $1.68. Synthetic Biologics has a 12-month low of $0.82 and a 12-month high of $3.05. The company’s market capitalization is $78.38 million.
Synthetic Biologics (NYSEMKT:SYN) last issued its quarterly earnings results on Tuesday, November 1st. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.01. On average, equities research analysts predict that Synthetic Biologics will post ($0.35) earnings per share for the current year.
A hedge fund recently raised its stake in Synthetic Biologics stock. UBS Group AG raised its stake in Synthetic Biologics Inc (NYSEMKT:SYN) by 378.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 288,367 shares of the company’s stock after buying an additional 228,037 shares during the period. UBS Group AG owned about 0.32% of Synthetic Biologics worth $680,000 as of its most recent filing with the SEC.